Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Al
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, spe
| Agency | National Institutes of Health |
|---|---|
| Status | Posted |
| Opportunity number | PAR-25-346 |
| Posted date | 12/11/2024 |
| Application deadline | Jan 07, 2028 12:00:00 AM EST |
| Award ceiling | none |
| Award floor | none |
| Who can apply | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); R |
| Assistance Listing (CFDA) | 93.394, 93.393, 93.121, 93.396, 93.395, 93.399 |
| Description | Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. |
| Agency contact | grantsinfo@nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/357651 |